They also further indicate that RUNX1 has the potential to be combined with chemotherapy drugs in the clinical treatment of ovarian cancer, thereby bringing better prognosis and quality of life to patients with ovarian cancer (Figure 3). This evidence concerns the gene RUNX1 and ovarian cancer.